A Phase I, Open-label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Oral Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label
To assess the effect of various degrees of impairment in hepatic function as measured by the National Cancer Institute-Cancer Therapy Evaluation Program (NCI-CTEP) criteria, on the pharmacokinetics of panobinostat.
first 7 days
United States: Food and Drug Administration
|University of Utah / Huntsman Cancer Institute||Salt Lake City, Utah 84103|